RAY121 is named as an intervention in 2 current clinical trials in our Germany, France, Spain, Italy, Netherlands, Poland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Japan, Taiwan, Australia and USA registers. 1 is recruiting patients now. All registered phases are Phase 1. The lead sponsor is Chugai Pharmaceutical. The most-studied condition is Antiphospholipid Syndrome (APS).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417 · ClinicalTrials.gov ↗ · Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS)
|
Phase 1 | Recruiting | Chugai Pharmaceutical | USA, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Japan, Taiwan, Australia |
|
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
NCT06723106 · ClinicalTrials.gov ↗ · Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS)
|
Phase 1 | By invitation | Chugai Pharmaceutical | Germany, France, Spain, Italy, Netherlands, Poland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Japan, Taiwan, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Chugai Pharmaceutical | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Germany, France, Spain, Italy, Netherlands, Poland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Japan, Taiwan, Australia and USA registers name RAY121 as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Poland, 1 with sites in Austria, 1 with sites in Czechia, 1 with sites in Norway, 1 with sites in Portugal, 1 with sites in Turkey, 1 with sites in Canada, 1 with sites in Japan, 1 with sites in Taiwan, 1 with sites in Australia and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Chugai Pharmaceutical. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how RAY121 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RAY121 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RAY121 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.